the use of dimiracetam in the treatment of chronic pain is disclosed . at doses higher than those previously disclosed in relation with its cognition enhancing activity , dimiracetam was able to completely revert hyperalgesia or allodynia associated with several animal models of chronic pain . dimiracetam showed high activity in iatrogenic neuropathies associated with antiviral and chemotherapeutic drug treatments and in painful conditions caused by osteoarthritis . in addition , dimiracetam was devoid of toxicity even at doses 10 - fold higher than the highest therapeutic dose . the possibility of treating such debilitating pathologies with a highly effective and essentially non - toxic compound is therefore disclosed .